Barry G. Arnason to Adult
This is a "connection" page, showing publications Barry G. Arnason has written about Adult.
Connection Strength
0.262
-
Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult Scler. 2010 Jan; 16(1):30-8.
Score: 0.020
-
Terbutaline in myasthenia gravis: a pilot study. J Neurol Sci. 2009 Feb 15; 277(1-2):150-4.
Score: 0.018
-
Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis. Arch Neurol. 2001 Jan; 58(1):87-90.
Score: 0.011
-
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. Mult Scler. 2019 04; 25(4):565-573.
Score: 0.009
-
Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology. 1996 Dec; 47(6):1463-8.
Score: 0.008
-
Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol. 2016 Jul; 263(7):1418-26.
Score: 0.008
-
Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology. 1995 Dec; 45(12):2173-7.
Score: 0.007
-
Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurol. 2015 Dec; 72(12):1458-65.
Score: 0.007
-
Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. J Neurol. 2015 Nov; 262(11):2466-71.
Score: 0.007
-
Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology. 1995 Jun; 45(6):1097-100.
Score: 0.007
-
Interferon gamma- and interleukin-4-secreting cells in multiple sclerosis. J Neuroimmunol. 1993 Jul; 46(1-2):123-8.
Score: 0.006
-
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study. J Neurol. 2013 Jul; 260(7):1838-45.
Score: 0.006
-
Antibody-secreting cells to acetylcholine receptor and to presynaptic membrane receptor in seronegative myasthenia gravis. J Neuroimmunol. 1993 Mar; 43(1-2):145-9.
Score: 0.006
-
Increased muscarinic cholinergic receptor density on CD4+ lymphocytes in progressive multiple sclerosis. J Neuroimmunol. 1992 Feb; 36(2-3):171-7.
Score: 0.006
-
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011 Dec; 70(6):897-912.
Score: 0.006
-
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler. 2012 Feb; 18(2):181-95.
Score: 0.006
-
Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. Mult Scler. 2011 Dec; 17(12):1504-13.
Score: 0.005
-
Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28- suppressor cell. Ann Neurol. 1991 Jul; 30(1):42-7.
Score: 0.005
-
Interferon ß-1b and glatiramer acetate effects on permanent black hole evolution. Neurology. 2011 Apr 05; 76(14):1222-8.
Score: 0.005
-
Sympathetic skin responses are decreased and lymphocyte beta-adrenergic receptors are increased in progressive multiple sclerosis. Ann Neurol. 1990 Apr; 27(4):366-72.
Score: 0.005
-
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009 Oct; 8(10):889-97.
Score: 0.005
-
Comparison of sympathetic skin response with quantitative sudomotor axon reflex test in diabetic neuropathy. Muscle Nerve. 1989 May; 12(5):420-3.
Score: 0.005
-
Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler. 2008 Jul; 14(6):809-14.
Score: 0.004
-
Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. Clin Ther. 2008 Jun; 30(6):1102-12.
Score: 0.004
-
HLA antigens in narcolepsy. Neurology. 1987 Dec; 37(12):1858-60.
Score: 0.004
-
Suppressor and cytolytic cell function in multiple sclerosis. Effects of cyclosporine A and interleukin 2. J Clin Invest. 1986 Aug; 78(2):582-6.
Score: 0.004
-
Multiple sclerosis: activated cells in cerebrospinal fluid in acute exacerbations. Ann Neurol. 1985 Dec; 18(6):722-5.
Score: 0.004
-
Effect of myasthenia serum and anti-acetylcholine receptor monoclonal antibody on the distributions of T-cell subsets in myasthenia patients and normal subjects. Asian Pac J Allergy Immunol. 1985 Jun; 3(1):30-6.
Score: 0.004
-
Multiple sclerosis: relation of in vitro IgG secretion to T suppressor cell number and function. Neurology. 1984 Sep; 34(9):1155-60.
Score: 0.003
-
Low T8 antigen density on lymphocytes in active multiple sclerosis. Ann Neurol. 1984 Aug; 16(2):242-9.
Score: 0.003
-
Analysis of T regulator cell surface markers and functional properties in multiple sclerosis. J Neuroimmunol. 1984 Apr; 6(2):93-103.
Score: 0.003
-
A biochemically distinct sub-population of neurons in the human substantia gelatinosa. Study with G-6-PD histochemistry. J Neurol Sci. 1982 Aug; 55(2):175-83.
Score: 0.003
-
Muscle acid protease activity in amyotrophic lateral sclerosis: correlation with clinical and pathologic features. Neurology. 1982 Aug; 32(8):901-3.
Score: 0.003
-
Modulation of T-lymphocyte differentiation antigens: potential relevance for multiple sclerosis. Proc Natl Acad Sci U S A. 1982 May; 79(10):3330-4.
Score: 0.003
-
Defective mitogenic responses in myasthenia gravis and multiple sclerosis. Ann Neurol. 1982 May; 11(5):456-62.
Score: 0.003
-
Multiple sclerosis: current concepts and management. Hosp Pract (Off Ed). 1982 Feb; 17(2):81-9.
Score: 0.003
-
Influence of azathioprine (imuran) on in vitro immune function in multiple sclerosis. Ann Neurol. 1982 Feb; 11(2):177-81.
Score: 0.003
-
Generation of suppressor cells by aggregated human globulin. Clin Exp Immunol. 1981 Feb; 43(2):351-6.
Score: 0.003
-
Comparison of agar gel electrophoresis and isoelectric focusing in multiple sclerosis and subacute sclerosing panencephalitis. Ann Neurol. 1981 Jan; 9(1):34-41.
Score: 0.003
-
Immunoregulation in multiple sclerosis. Ann Neurol. 1980 Sep; 8(3):237-40.
Score: 0.003
-
Reduced T-lymphocyte cell reactivity as a function of human aging. Cell Immunol. 1980 Aug 15; 54(1):184-92.
Score: 0.003
-
Changes in concanavalin A capping of human lymphocytes with age. Mech Ageing Dev. 1980 Apr; 12(4):331-7.
Score: 0.003
-
Huntington's disease: abnormality of lymphocyte capping. Ann Neurol. 1979 Nov; 6(5):447-50.
Score: 0.002
-
Suppressor cell function in man: evidence for altered sensitivity of responder cells with age. Clin Immunol Immunopathol. 1979 Jun; 13(2):119-24.
Score: 0.002
-
Cellular immunity to acetylcholine receptor in myasthenia gravis: relationship to histocompatibility type and antigenic site. Neurology. 1979 Mar; 29(3):291-6.
Score: 0.002
-
Mitogen responsiveness and suppressor cell function in multiple sclerosis. Influence of age and disease activity. Neurology. 1978 Oct; 28(10):999-1003.
Score: 0.002
-
Suppressor cell function in multiple sclerosis. Ann Immunol (Paris). 1978 Feb-Mar; 129(2-3):159-70.
Score: 0.002
-
Circulating suppressor cells in man as a function of age. Clin Immunol Immunopathol. 1978 Jan; 9(1):134-41.
Score: 0.002
-
Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology. 1996 Jul; 47(1):129-39.
Score: 0.002
-
Cellular immunity in myasthenia gravis. Response to purified acetylcholine receptor and autologous thymocytes. N Engl J Med. 1976 Mar 25; 294(13):694-8.
Score: 0.002
-
Neutralizing antibodies to poliovirus and mumps virus in amyotrophic lateral sclerosis. J Neurol Sci. 1974 Dec; 23(4):537-40.
Score: 0.002
-
Cell-mediated immunity in polymyositis. Creatine phosphokinase release from muscle cultures. Arch Neurol. 1974 Sep; 31(3):192-6.
Score: 0.002
-
Histocompatibility types and measles antibodies in multiple sclerosis and optic neuritis. J Neurol Sci. 1974 Aug; 22(4):419-28.
Score: 0.002
-
The human-severe combined immunodeficiency myasthenic mouse model: a new approach for the study of myasthenia gravis. Ann Neurol. 1993 Jul; 34(1):48-56.
Score: 0.002
-
Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol. 1991 Apr; 32(1):67-74.
Score: 0.001
-
Comparison of T8+ cell-mediated suppressor and cytotoxic functions in multiple sclerosis. J Neuroimmunol. 1986 Sep; 12(3):215-24.
Score: 0.001
-
Mechanisms responsible for reduced in vitro immunoglobulin secretion in aged humans. Mech Ageing Dev. 1983 Sep; 23(1):11-9.
Score: 0.001
-
Age-related changes in in vitro immunoglobulin secretion: comparison of responses to T-dependent and T-independent polyclonal activators. Cell Immunol. 1982 Dec; 74(2):398-403.
Score: 0.001
-
Autosomal dominant cerebrovascular amyloidosis: properties of peripheral blood lymphocytes. Ann Neurol. 1980 May; 7(5):436-40.
Score: 0.001
-
Parainfluenza, histocompatibility, and multiple sclerosis. Association of parainfluenza antibodies and histocompatibility types in MS and optic neuritis. Arch Neurol. 1974 Apr; 30(4):327-9.
Score: 0.000
-
The role of thymectomy in the treatment of myasthenia gravis. Ann N Y Acad Sci. 1971 Sep 15; 183:308-15.
Score: 0.000